Investment Thesis
Alector is a clinical-stage biopharmaceutical company with $1.0M revenue against -$49.8M operating cash burn, indicating severe losses typical of pre-commercialization biotech. While the $77.0M cash position provides ~18 months of runway with a strong 5.25x current ratio, the absence of revenue growth and negative profitability across all metrics creates substantial execution risk requiring successful drug development and commercialization.
Strengths
- Strong liquidity position with 5.25x current ratio providing near-term financial stability
- Adequate cash reserves of $77.0M reduce immediate financing pressure
- Moderate debt burden with 0.80x debt-to-equity ratio limiting financial leverage risk
Risks
- Catastrophic cash burn rate of -$49.8M annually with only 18 months of funding runway at current burn rate
- Minimal revenue generation of $1.0M with zero growth trajectory and no visible path to profitability
- Clinical-stage development risk: success depends entirely on drug pipeline approval and market acceptance with no de-risking milestones visible
- Stockholders' equity of only $10.4M relative to $229.5M liabilities indicates severe capital structure stress
Key Metrics to Watch
- Monthly cash burn rate trends and runway extension through financing or partnerships
- Clinical trial progression and FDA milestone achievements for lead programs
- Revenue generation timeline and partnership deals demonstrating commercialization progress
- Stockholders' equity trajectory and capital raising activity
Financial Metrics
Revenue
1.0M
Net Income
-22.9M
EPS (Diluted)
$-0.21
Free Cash Flow
-49.9M
Total Assets
239.9M
Cash
77.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,382.3%
Net Margin
-2,192.2%
ROE
-220.9%
ROA
-9.6%
FCF Margin
-4,773.5%
Balance Sheet & Liquidity
Current Ratio
5.25x
Quick Ratio
5.25x
Debt/Equity
0.80x
Debt/Assets
95.7%
Interest Coverage
N/A
Long-term Debt
8.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:31:56.453104 |
Data as of: 2026-03-31 |
Powered by Claude AI